The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database

Publikation: Beiträge in ZeitschriftenZeitschriftenaufsätzeForschung

Standard

The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database. / Spielhagen, Christin; Schwahn, Christian; Möller, Kristin et al.
in: Growth Hormone and IGF Research, Jahrgang 21, Nr. 1, 01.02.2011, S. 1-10.

Publikation: Beiträge in ZeitschriftenZeitschriftenaufsätzeForschung

Harvard

Spielhagen, C, Schwahn, C, Möller, K, Friedrich, N, Kohlmann, T, Moock, J, Kołtowska-Häggström, M, Nauck, M, Buchfelder, M & Wallaschofski, H 2011, 'The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database', Growth Hormone and IGF Research, Jg. 21, Nr. 1, S. 1-10. https://doi.org/10.1016/j.ghir.2010.10.005

APA

Spielhagen, C., Schwahn, C., Möller, K., Friedrich, N., Kohlmann, T., Moock, J., Kołtowska-Häggström, M., Nauck, M., Buchfelder, M., & Wallaschofski, H. (2011). The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database. Growth Hormone and IGF Research, 21(1), 1-10. https://doi.org/10.1016/j.ghir.2010.10.005

Vancouver

Spielhagen C, Schwahn C, Möller K, Friedrich N, Kohlmann T, Moock J et al. The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database. Growth Hormone and IGF Research. 2011 Feb 1;21(1):1-10. doi: 10.1016/j.ghir.2010.10.005

Bibtex

@article{444d844b2bdd4198a917f6d0eef446d2,
title = "The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database",
abstract = "Objective: To evaluate the treatment effects of long-term growth hormone (GH) replacement therapy in adults with GH deficiency (GHD) who were followed in KIMS Germany (Pfizer International Metabolic Database), a national surveillance study. Design: The analysis was performed using baseline and long-term data (range: 4-10. years) of 440 consecutively documented patients (216 women and 224 men) with GHD, aged 20 to 49. years, enrolled in KIMS Germany. Serum insulin-like growth factor I (IGF-I), fasting blood glucose, fasting serum total cholesterol and low-density lipoprotein cholesterol (LDL-C) as well as body mass index (BMI), waist circumference (WC) and hip circumference (HC) at baseline and at last visit were studied. Furthermore, QoL-AGHDA score was determined to assess quality-of-life (QoL). Results: The mean dose of GH over all years was 0.41. mg per day in women and 0.37. mg per day in men. IGF-I and IGF-I SDS levels (standard deviation score) increased significantly (p < 0.001) during GH treatment. The QoL-AGHDA score decreased significantly (p < 0.001), indicating long-lasting improvement in QoL. In total cholesterol, LDL-C and fasting blood glucose, no significant changes were found. Only six patients developed type 2 diabetes during follow-up. Females and males similarly increased significantly in BMI, WC and HC. During GH treatment, recurrences of pituitary or central nervous system tumours or further de novo neoplasia were reported in 6 or 11 patients, respectively. The number of the most frequently reported GH treatment-associated adverse events was low. Conclusion: These observational data show long-term beneficial effects of GH replacement therapy on QoL and show no significant effects on total cholesterol, LDL-C or BMI, WC and HC. Additionally, our data indicate that GH replacement therapy in adults is well tolerated.",
keywords = "Health sciences, Adult, Body Weights and Measures, Databases, Factual, Dose-Response Relationship, Drug, Dwarfism, Pituitary, Female, Follow-Up Studies, Germany, Hormone Replacement Therapy, Human Growth Hormone, Humans, Hypopituitarism, Insulin-Like Growth Factor I, Male, Middle Aged, Quality of Life, Risk Assessment, Time Factors, Young Adult",
author = "Christin Spielhagen and Christian Schwahn and Kristin M{\"o}ller and Nele Friedrich and Thomas Kohlmann and J{\"o}rn Moock and Maria Ko{\l}towska-H{\"a}ggstr{\"o}m and Matthias Nauck and Michael Buchfelder and Henri Wallaschofski",
note = "Copyright {\textcopyright} 2010 Growth Hormone Research Society. Published by Elsevier Ltd. All rights reserved.",
year = "2011",
month = feb,
day = "1",
doi = "10.1016/j.ghir.2010.10.005",
language = "English",
volume = "21",
pages = "1--10",
journal = "Growth Hormone and IGF Research",
issn = "1096-6374",
publisher = "Churchill Livingstone",
number = "1",

}

RIS

TY - JOUR

T1 - The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency

T2 - results of the German KIMS database

AU - Spielhagen, Christin

AU - Schwahn, Christian

AU - Möller, Kristin

AU - Friedrich, Nele

AU - Kohlmann, Thomas

AU - Moock, Jörn

AU - Kołtowska-Häggström, Maria

AU - Nauck, Matthias

AU - Buchfelder, Michael

AU - Wallaschofski, Henri

N1 - Copyright © 2010 Growth Hormone Research Society. Published by Elsevier Ltd. All rights reserved.

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Objective: To evaluate the treatment effects of long-term growth hormone (GH) replacement therapy in adults with GH deficiency (GHD) who were followed in KIMS Germany (Pfizer International Metabolic Database), a national surveillance study. Design: The analysis was performed using baseline and long-term data (range: 4-10. years) of 440 consecutively documented patients (216 women and 224 men) with GHD, aged 20 to 49. years, enrolled in KIMS Germany. Serum insulin-like growth factor I (IGF-I), fasting blood glucose, fasting serum total cholesterol and low-density lipoprotein cholesterol (LDL-C) as well as body mass index (BMI), waist circumference (WC) and hip circumference (HC) at baseline and at last visit were studied. Furthermore, QoL-AGHDA score was determined to assess quality-of-life (QoL). Results: The mean dose of GH over all years was 0.41. mg per day in women and 0.37. mg per day in men. IGF-I and IGF-I SDS levels (standard deviation score) increased significantly (p < 0.001) during GH treatment. The QoL-AGHDA score decreased significantly (p < 0.001), indicating long-lasting improvement in QoL. In total cholesterol, LDL-C and fasting blood glucose, no significant changes were found. Only six patients developed type 2 diabetes during follow-up. Females and males similarly increased significantly in BMI, WC and HC. During GH treatment, recurrences of pituitary or central nervous system tumours or further de novo neoplasia were reported in 6 or 11 patients, respectively. The number of the most frequently reported GH treatment-associated adverse events was low. Conclusion: These observational data show long-term beneficial effects of GH replacement therapy on QoL and show no significant effects on total cholesterol, LDL-C or BMI, WC and HC. Additionally, our data indicate that GH replacement therapy in adults is well tolerated.

AB - Objective: To evaluate the treatment effects of long-term growth hormone (GH) replacement therapy in adults with GH deficiency (GHD) who were followed in KIMS Germany (Pfizer International Metabolic Database), a national surveillance study. Design: The analysis was performed using baseline and long-term data (range: 4-10. years) of 440 consecutively documented patients (216 women and 224 men) with GHD, aged 20 to 49. years, enrolled in KIMS Germany. Serum insulin-like growth factor I (IGF-I), fasting blood glucose, fasting serum total cholesterol and low-density lipoprotein cholesterol (LDL-C) as well as body mass index (BMI), waist circumference (WC) and hip circumference (HC) at baseline and at last visit were studied. Furthermore, QoL-AGHDA score was determined to assess quality-of-life (QoL). Results: The mean dose of GH over all years was 0.41. mg per day in women and 0.37. mg per day in men. IGF-I and IGF-I SDS levels (standard deviation score) increased significantly (p < 0.001) during GH treatment. The QoL-AGHDA score decreased significantly (p < 0.001), indicating long-lasting improvement in QoL. In total cholesterol, LDL-C and fasting blood glucose, no significant changes were found. Only six patients developed type 2 diabetes during follow-up. Females and males similarly increased significantly in BMI, WC and HC. During GH treatment, recurrences of pituitary or central nervous system tumours or further de novo neoplasia were reported in 6 or 11 patients, respectively. The number of the most frequently reported GH treatment-associated adverse events was low. Conclusion: These observational data show long-term beneficial effects of GH replacement therapy on QoL and show no significant effects on total cholesterol, LDL-C or BMI, WC and HC. Additionally, our data indicate that GH replacement therapy in adults is well tolerated.

KW - Health sciences

KW - Adult

KW - Body Weights and Measures

KW - Databases, Factual

KW - Dose-Response Relationship, Drug

KW - Dwarfism, Pituitary

KW - Female

KW - Follow-Up Studies

KW - Germany

KW - Hormone Replacement Therapy

KW - Human Growth Hormone

KW - Humans

KW - Hypopituitarism

KW - Insulin-Like Growth Factor I

KW - Male

KW - Middle Aged

KW - Quality of Life

KW - Risk Assessment

KW - Time Factors

KW - Young Adult

UR - http://www.scopus.com/inward/record.url?scp=79951726718&partnerID=8YFLogxK

U2 - 10.1016/j.ghir.2010.10.005

DO - 10.1016/j.ghir.2010.10.005

M3 - Journal articles

C2 - 21093334

VL - 21

SP - 1

EP - 10

JO - Growth Hormone and IGF Research

JF - Growth Hormone and IGF Research

SN - 1096-6374

IS - 1

ER -

DOI